Glaukos Announces Positive Topline Outcomes for Both Phase 3 Pivotal Trials of iDose TR, Achieving Primary Efficacy Endpoints and Demonstrating Favorable Tolerability and Safety ProfilesBusiness Wire • 09/07/22
Glaukos Announces More Than 1 Million iStent® Technologies Implanted WorldwideBusiness Wire • 09/06/22
Burns & Levinson Represents iVeena Delivery Systems, Inc. in Strategic Licensing Agreement with Glaukos CorporationPRNewsWire • 08/29/22
Glaukos Corporation (GKOS) CEO Tom Burns on Q2 2022 Results Earnings Call TranscriptSeeking Alpha • 08/04/22
Glaukos to Release Second Quarter 2022 Financial Results after Market Close on August 3Business Wire • 07/13/22
Glaukos Announces Participation in the Piper Sandler Virtual Ophthalmology SymposiumBusiness Wire • 05/20/22
Glaukos Corporation (GKOS) CEO Tom Burns on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/04/22
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2022 American Society of Cataract and Refractive Surgery Annual MeetingBusiness Wire • 04/21/22